Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2026

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands, except share

and per share amounts):

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Basic:
Net income (loss) attributable to common stockholders	$44,516	$(23,478)	$101,265	$90,855
Weighted-average number of common shares	140,593,457	141,226,862	141,180,120	140,569,409
Net income (loss) per common share	$0.32	$(0.17)	$0.72	$0.65
Diluted:
Net income (loss) attributable to common stockholders	$44,516	$(23,478)	$101,265	$90,855
Weighted-average number of common shares	141,704,656	141,226,862	142,174,942	141,242,065
Net income (loss) per common share	$0.31	$(0.17)	$0.71	$0.64

Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method

The following table sets forth the components of the denominator for the computation of basic and diluted net income (loss)

per share for net income (loss) attributable to Ardent Health, Inc. stockholders:

		Three Months Ended September 30,		Nine Months Ended September 30,
		2026	2025	2026	2025
Weighted-average number of common shares - basic		140,593,457	141,226,862	141,180,120	140,569,409
Effect of dilutive securities(1)		1,111,199	—	994,822	672,656
Weighted-average number of common shares - diluted		141,704,656	141,226,862	142,174,942	141,242,065
(1)	The effect of dilutive securities does not reflect weighted-average potential common shares from restricted stock and restricted stock units of 779,696 and 3,034,583 for the three months ended September 30, 2026 and 2025, respectively, and 1,918,662 and 1,439,373 for the nine months ended September 30, 2026 and 2025, respectively, because their effect was antidilutive as calculated under the treasury stock method.